Jeko 1

Manufactured by American Type Culture Collection

Sourced in United States, Germany, China

The Jeko-1 is a cell line derived from a patient with mantle cell lymphoma. It is a suspension cell line and can be used for research purposes related to this type of lymphoma.

Automatically generated - may contain errors

Lab products found in correlation

Close spelling variants of this product

JeKo-1 cells (2 citations)

80 protocols using jeko 1

Western Blot Analysis of BCR Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols

Luxeptinib was provided by Aptose Biosciences. Ibrutinib (#HY-10997) was purchased from MedChem Express. Goat anti-human IgM (#109-005-043) was purchased from Jackson ImmunoResearch. Human lymphoma cell lines SU-DHL-6 (#CRL-2959), JeKo-1 (#CRL-3006), RL (#CRL-2261) and Fetal Bovine Serum (#30–2020) were obtained from ATCC. SU-DHL-6 is a human lymphoblast-like cell line, JeKo-1 is a mantle cell lymphoma cell line and RL is a human non-Hodgkin’s lymphoma B cell line. RPMI-1640 medium (#11875–093) and penicillin/streptomycin (#15070063) were purchased from Thermo Fisher Scientific. Antibodies against p-BTK (Y223) (#87141), BTK (#56044), p-PLCγ2 (#3871), p-SYK (#2710), SYK (#80460), p-BLNK (#3601), BLNK (#36438), p-CD79A (#5173), p-LYN/LCK/HCK/BLK (#70926), p-LYN (Y507) (#2731), LYN (#2796, #4576), pSrc family (#6943) and GAPDH (#2118) were purchased from Cell Signaling Technology. Phospho-BTK (Y551) (#ab40770) was purchased from Abcam. PLCγ2 (#sc-5283) and CD79A (#sc-20064) were purchased from Santa Cruz Biotechnology. All other reagents and chemicals used were of analytical grade and were obtained from Sigma-Aldrich or Thermo Fisher Scientific.

Sonowal H., Rice W.G, & Howell S.B. (2023). Luxeptinib interferes with LYN-mediated activation of SYK and modulates BCR signaling in lymphoma. PLOS ONE, 18(3), e0277003.

+ Open protocol

+ Expand

Culturing Human Lymphoma Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

The human Burkitt lymphoma cell lines Daudi (ATCC^® CCL-213™), Namalwa (ATCC^® CRL-1432™), Ramos (RA 1) (ATCC^® CRL-1596™), Raji (ATCC^® CCL-86™), the JeKo-1 (ATCC^® CRL-3006™) human mantle cell lymphoma cell line, and the RS4;11 (ATCC^® CRL-1432™) human acute lymphoblastic leukemia cell line were purchased from the ATCC (American Type Culture Collection, Manassas, VA, USA). All cells were maintained according to the ATCC instructions in an incubator at 37 °C with a humidified atmosphere of 5% CO₂ in air. Tissue culture flasks and dishes were purchased from Sarstedt, Inc. (Newton, NC, USA). Heat-inactivated fetal bovine serum (FBS) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Other cell culture media and reagents were purchased from Thermo Fisher Scientific (Waltham, MA, USA).

Chen L.M, & Chai K.X. (2023). Exosome-Mediated Activation of the Prostasin-Matriptase Serine Protease Cascade in B Lymphoma Cells. Cancers, 15(15), 3848.

+ Open protocol

+ Expand

Characterization of Lymphoma Cell Lines

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

Raji (Burkitt lymphoma), Jurkat (T cell lymphoma), Jeko-1 (mantle cell lymphoma) and K562 (CD20-negative erythroid leukemia) tumor cell lines were purchased from ATCC (Manassas, VA). Granta-519 (mantle cell lymphoma) cell was obtained from DSMZ (Braunschweig, Germany). TM-LCL is an EBV-transformed lymphoblastoid cell line optimized for expansion of T cell cultures.^{37 (link), 38 (link)} Cells were cultured in RPMI 1640 with 10% FBS, 1% penicillin/streptomycin, and 1% L-glutamine, and incubated in a humidified atmosphere containing 5% CO₂ at 37°C. The generation of K562-CD64 cells was previously described.^{39 (link)} Raji-ffLuc and Granta-ffLuc were generated by transduction with a retroviral vector encoding firefly luciferase (ffLuc), Thy1.1, and neomycin resistance gene^{36 (link), 40 (link)} and maintained and selected with 0.8 mg/ml G418 (Promega, Madison, WI). All cell lines were routinely assessed over the course of these experiments to confirm the expected surface marker expression by flow cytometry.

Lee S.Y., Olsen P., Lee D.H., Kenoyer A.L., Budde L.E., O’Steen S., Green D.J., Heimfeld S., Jensen M.C., Riddell S.R., Press O.W, & Till B.G. (2018). Preclinical optimization of a CD20-specific chimeric antigen receptor vector and culture conditions. Journal of immunotherapy (Hagerstown, Md. : 1997), 41(1), 19-31.

+ Open protocol

+ Expand

Cell Line Authentication and Culture

Check if the same lab product or an alternative is used in the 5 most similar protocols

MDA-MB-231, PC3, DU145, MCF7, H82, H146, L1236, H526, VCaP, Jeko-1, SUM159, HDLM2, and HEK293T cells were purchased from ATCC in 2016. C4-2 was a gift from Dr. Leland W. Chang. All cell lines were tested and authenticated at the University of Arizona Genetic Core (Tucson, AZ) in 2017 and 2019. PC3, and MDA-MB-231 were cultured in DMEM (GenDEPOT) supplemented with 10% FBS (GenDEPOT). DU145, C4-2, MCF7, H82, H146, L1236, H526, Jeko-1 and HDLM2 were cultured in RPMI 1640 (GenDEPOT) supplemented with 10% FBS (GenDEPOT). SUM159 was cultured in Ham’s F-12 (Gibco) with 10% FBS. All cells were frozen at passage 2-3 and used within 20 passages after each thawing. The cells were cultured in a 37°C incubator and a humidified atmosphere with 5% CO₂. All cell lines were authenticated by the University of Arizona Genetics Core using short tandem repeat (STR) profiling. Cell lines were mycoplasma negative as reported by routine lab tests.

Li Q., Liu K.Y., Liu Q., Wang G., Jiang W., Meng Q., Yi Y., Yang Y., Wang R., Zhu S., Li C., Wu L., Zhao D., Yan L., Zhang L., Kim J.S., Zu X., Kozielski A.J., Qian W., Chang J.C., Patnaik A., Chen K, & Cao Q. (2020). Antihistamine Drug Ebastine inhibits cancer growth by targeting Polycomb Group Protein EZH2. Molecular cancer therapeutics, 19(10), 2023-2033.

+ Open protocol

+ Expand

Ibrutinib Resistance in Mantle Cell Lymphoma

Check if the same lab product or an alternative is used in the 5 most similar protocols

Ibrutinib-resistant MCL cell lines (MAVER-1 and Granta-519), Ibrutinib-intermediated MCL cell lines (Mino and REC-1), and Ibrutinib-sensitive MCL cell lines (Jeko-1) were procured from the ATCC (Manassas, VA, USA). These cells were kept in RPMI-1640 (GIBCO, Grand Island, NY, USA) contained with 10% FBS in the humidified 5% CO₂ environment at 37 °C. 5 ×10⁴ Jeko-1 and MAVER-1 cells were incubated with Ibrutinib (0.6 µmol/L; Selleck, TX, USA) for 48 h.

Zhang Y., Lu P., Zhou Y, & Zhang L. (2021). Inhibition of LINK-A lncRNA overcomes ibrutinib resistance in mantle cell lymphoma by regulating Akt/Bcl2 pathway. PeerJ, 9, e12571.

+ Open protocol

+ Expand

Transduced Leukemia and Lymphoma Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following cells lines were purchased from ATCC: acute lymphoblastic leukemia cell line Nalm6 (Manassas, VA, USA) and mantle cell lymphoma cell line Jeko-1 (Manassas, VA, USA). Both cell lines (Jeko-1 and Nalm6) were transduced with a firefly luciferase ZsGreen (Addgene, Cambridge, MA, USA) and then sorted to obtain >99% positive population as previously described.^{17 (link)} Cell lines were cultured in R10 or R20 (RPMI 1640, Gibco, Gaithersburg, MD, US), 10% or 20% Fetal Bovine Serum (FBS, Millipore Sigma, Ontario, Canada), respectively, and 1% Penicillin-Streptomycin-Glutamine (Gibco, Gaithersburg, MD, US). Cell lines were kept in culture up to 20 passages, and fresh aliquots were thawed every 7–8 weeks. Cell lines were authenticated by the manufacturer and routinely checked for phenotype by flow cytometry. Cell lines were tested monthly for mycoplasma. The use of recombinant DNA in the laboratory was approved by the Mayo Clinic Institutional Biosafety Committee (IBC).

Cox M.J., Roman C.M., Tapper E.E., Siegler E.L., Chappell D., Durrant C., Ahmed O., Sinha S., Mwangi R., Scott N.S., Hefazi M., Schick K.J., Horvei P., Ruff M.W., Can I., Adada M., Bezerra E., Fonkoua L.A., Parikh S.A., Kay N.E., Sakemura R, & Kenderian S.S. (2022). GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity. Leukemia, 36(6), 1635-1645.

+ Open protocol

+ Expand

Investigating Mantle Cell Lymphoma Using Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human CD19⁺ mantle cell lymphoma cell line JeKo‐1 (cat# CRL‐3006) and human CD19⁻ cell line CCRF‐CEM (cat# CCL‐119) were purchased from ATCC (Manassas, VA, USA). Human CD19⁻ cell line M14 and MD‐MBA‐231 were generously provided by Soldano Ferrone (Massachusetts General Hospital). mAbs used in this study are listed in Table 1.

Zheng Q., Wang Z., Zhang H., Huang Q., Madsen J.C., Sachs D.H., Huang C.A, & Wang Z. (2017). Diphtheria toxin‐based anti‐human CD19 immunotoxin for targeting human CD19+ tumors. Molecular Oncology, 11(5), 584-594.

+ Open protocol

+ Expand

Culturing Mantle Cell Lymphoma and Stromal Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mantle cell lymphoma cell line Jeko-1 was purchased from ATCC (Manassas, VA, USA) and maintained in RPMI-1640 containing 20% fetal bovine serum (FBS; Gibco by Life Technologies, Carlsbad, CA, USA) and 1% penicillin-streptomycin (Gibco by Life Technologies). Cultures were maintained by the addition of fresh replacement medium every 2 to 3 days. The murine stromal cell line M2-10B4 was purchased from ATCC (Manassas, VA, USA). Cells were maintained in RPMI-1640 containing 10% FBS and 1% penicillin-streptomycin. Cultures were maintained by removing medium, rinsing with 0.25% Trypsin-EDTA solution (Gibco by Life Technologies) followed by the addition of a fresh culture medium every 2 to 3 days.

Kim Y.R, & Eom K.S. (2014). Simultaneous Inhibition of CXCR4 and VLA-4 Exhibits Combinatorial Effect in Overcoming Stroma-Mediated Chemotherapy Resistance in Mantle Cell Lymphoma Cells. Immune Network, 14(6), 296-306.

+ Open protocol

+ Expand

Culturing Mantle Cell Lymphoma Cells

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mantle cell lymphoma cell line Jeko-1 was purchased from ATCC. SP49 was provided by Dr. M. Wasik from the University of Pennsylvania. Stromal cell line HK was purchased from Cellosaurus. These cells and their Ibrutinib-resistant derivatives (Zhao et al., 2017 (link)) were cultured in RPMI-1640 (GIBCO-Invitrogen) with penicillin (100 U/ml) and streptomycin (100 μg/ml) and maintained at 37°C in 5% CO₂. Cell lines were routinely tested for mycoplasma using the Universal Mycoplasma Detection Kit from ATCC.

Zhao X., Wang M.Y., Jiang H., Lwin T., Park P.M., Gao J., Meads M.B., Ren Y., Li T., Sun J., Fahmi N.A., Singh S., Sehgal L., Wang X., Silva A.S., Sotomayor E.M., Shain K.H., Cleveland J.L., Wang M., Zhang W., Qi J., Shah B.D, & Tao J. (2021). Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma. Cell reports, 34(11), 108870.

+ Open protocol

+ Expand

Culturing Lymphoma Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

All lymphoma cell lines (JeKo-1, Raji, Daudi) were purchased from ATCC (Manassas, VA, USA) or DSMZ (Braunschweig, Germany), and Lenti-X 293T cells were purchased from (TaKaRa, Kusatsu, Shiga, Japan). All lymphoma cell lines were maintained in RPMI 1640 media and Lenti-X 293T cells were maintained in DMEM media. Media were supplemented with 10% heat-inactivated fetal bovine serum (ThermoFisher, Waltham, MA, USA), 2 mM L-glutamine, 1 mM sodium pyruvate, and 100 units/mL of penicillin and 100 µg/mL of streptomycin (all from Biochrom, Waltham, MA, USA), referred to as complete media.

Atar D., Mast A.S., Scheuermann S., Ruoff L., Seitz C.M, & Schlegel P. (2022). Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas. Biomedicines, 10(10), 2420.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!